

Drive Robotic Bronchoscopy Program Volumes

Lung cancer screening (LCS) programs are a critical way to evaluate high-risk patients before it is too late. However, the uptake of LCS nationwide is abysmally low (~6%) and ~50% of individuals who are ultimately diagnosed with lung cancer do not meet the criteria for screening.

Leading organizations who have invested in AI-driven incidental pulmonary nodule (IPN) programs, in which potentially cancerous findings surface outside of typical screening procedures, have found the most success in ensuring potential lung cancer patients are not falling through the cracks. Lung cancers are 9 times more likely to be found incidentally than from screenings. Therefore, if you do not have a well-designed IPN program, you are missing a significant number of bronchoscopy and surgical candidates. With a best-practice IPN program running alongside an LCS program, you can ensure that your robots are functioning at full capacity and your service lines are growing.



Using AI to Maximize Your Robot Investment: Success at Our Lady of the Lake





Our Lady of the Lake
REGIONAL MEDICAL CENTER

Our Lady of the Lake (OLOL) is one of the largest hospitals in the country, with over 900 beds and 365,000 radiology exams performed annually. In 2021, OLOL implemented Eon to efficiently manage both LDCT and IPN patients, ensuring timely follow-up, robust reporting, and seamless pathology data integration.

Eon's advanced AI dramatically increased the number of potential lung cancer patients identified from 132 patients in 2020 (pre-Eon) to 2156 in 2024 (annualized). This resulted in a 193% increase in OLOL's robotic bronchoscopy volume and a 33% increase in surgical volume. The net effect of increased volume driven by Eon and the investment in the Ion robot led to a 103% increase in cancer diagnosis. The continuous growth in the volume of lung nodule patients has allowed OLOL to maximize their robot investment and grow their thoracic surgery division.

Impact of Eon on Volumes and Stage Shift

■ FY 2021 Volume ■ FY 2024 Volume (YTD Annualized)



Stop Missing Catastrophic Illness with Eon

For more than 10 years, Eon has been the industry leader in establishing best practice incidental findings programs. Eon leverages data from millions of radiology scans to uncover abnormalities within your patient population across lung, pancreas, liver, thyroid, breast, cardiovascular conditions, and more. By using the most advanced computational linguistics technology, Eon accurately identifies potentially catastrophic findings, risk-stratifies patients for review, and creates custom care plans that drive patient volumes, adherence, and outcomes.

1.5M+
patients impacted

1k+
hospital sites

98.5%
accuracy in
abnormality detection

70+%
patient adherence
to care plan



Health system partners see meaningful increases in their robotic bronchoscopy and surgical volumes by leveraging this approach – while driving stage shift and positive patient outcomes.

Trusted by the Industry's Best:

Geisinger



Ascension

CHS Community
Health Systems

RWJBarnabas
HEALTH

BAPTIST HEALTH®

Lifepoint Health

uchealth

Hospital Sisters
HEALTH SYSTEM

HCA
Healthcare™

ROSWELL
PARK®
COMPREHENSIVE CANCER CENTER

What are you waiting for?

Reach out today for a **custom impact analysis** demonstrating how Eon can grow bronchoscopies, thoracic surgeries, cardiovascular surgeries, and other procedures at your facility.



eonhealth.com